Episode Details
Back to Episodes
143_ How Bud & Mary’s Became the First DEA-Licensed Cannabis MSO
Description
Bud and Mary_Duncan Mackie. PhD Director of Pharmacology & Experimental Therapeutics
Today, I’m joined by Dr. Duncan Mackie, Director of Pharmacology and Experimental Therapeutics at Bud & Mary's—an MSO with operations in Colorado, Michigan, Iowa, and Missouri.
Under Dr. Mackie’s leadership, Bud & Mary’s became the first cannabis company and multi-state operator to obtain a DEA research license—marking a major milestone for the industry.
With a PhD in pharmacology and deep expertise in drug discovery, molecular biology, and G-protein-coupled receptor pharmacology, Dr. Mackie is advancing our understanding of cannabinoids and their interaction with the endocannabinoid system. His work is helping to identify novel drug targets and explore the therapeutic potential of cannabis for a range of medical conditions.
Bud & Mary’s also applies this scientific insight to their product formulations, integrating cutting-edge research into what’s available on dispensary shelves.
In our conversation, we explore their approach to product development, the regulatory hurdles they face, and their long-term vision.
https://www.budmary.com/
https://www.linkedin.com/in/duncan-mackie-ph-d-3bb1892b/
The Innovating Cannabis podcast is produced and hosted by Pam Chmiel, a freelance writer and editor for the Cannabis Industry Journal.
Get in touch with pam@InnovatingCannabisPodcast.com.
Please like the show to help us reach more listeners🙏🏻
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.